M
Mark E. Cooper
Researcher at University of Queensland
Publications - 1514
Citations - 141899
Mark E. Cooper is an academic researcher from University of Queensland. The author has contributed to research in topics: Diabetes mellitus & Diabetic nephropathy. The author has an hindex of 158, co-authored 1463 publications receiving 124887 citations. Previous affiliations of Mark E. Cooper include University of Cambridge & University of Adelaide.
Papers
More filters
Journal ArticleDOI
Small-molecule inhibitors of the SOX18 transcription factor
Frank Fontaine,Jeroen Overman,Mehdi Moustaqil,Sreeman K. Mamidyala,Angela A. Salim,Kamesh Narasimhan,Nina Prokoph,Avril A. B. Robertson,Linda H.L. Lua,Kirill Alexandrov,Peter Koopman,Robert J. Capon,Emma Sierecki,Yann Gambin,Ralf Jauch,Ralf Jauch,Mark E. Cooper,Johannes Zuegg,Mathias Francois +18 more
TL;DR: In an attempt to modulate the activity of SOX18 TF, a known regulator of vascular growth in development and disease, a marine extract library is screened for potential small-molecule inhibitors and two compounds are identified, which inspired a series of synthetic SoX18 inhibitors.
Journal ArticleDOI
Metronidazole-triazole conjugates: Activity against Clostridium difficile and parasites
Angie M. Jarrad,Tomislav Karoli,Anjan Debnath,Chin Yen Tay,Johnny X. Huang,Geraldine Kaeslin,Alysha G. Elliott,Yukiko Miyamoto,Soumya Ramu,Angela M. Kavanagh,Johannes Zuegg,Lars Eckmann,Mark A. T. Blaskovich,Mark E. Cooper +13 more
TL;DR: Several new metronidazole-triazole conjugates (Mtz-Triazoles) have been identified with excellent broad spectrum antimicrobial and antiparasitic activity targeting Clostridium difficile, Entamoeba histolytica and Giardia lamblia.
Journal ArticleDOI
Myocardial infarction increases ACE2 expression in rat and humans [1] (multiple letters)
Journal ArticleDOI
Nox-4 and progressive kidney disease.
TL;DR: The role of Nox-4 as a target for renoprotection remains controversial, although recent positive preclinical data have stimulated increased interest in inhibiting the enzyme in clinical trials of renal disease.
Journal ArticleDOI
Structure–activity relationships for the binding of polymyxins with human α-1-acid glycoprotein
Mohammad Abul Kalam Azad,Johnny X. Huang,Mark E. Cooper,Kade D. Roberts,Philip E. Thompson,Roger L. Nation,Jian Li,Tony Velkov +7 more
TL;DR: The binding properties of the polymyxin class of antibiotics for human α-1-acid glycoprotein (AGP) using a combination of biophysical techniques are characterized, consistent with a role of this acute-phase reactant protein in the transport ofpolymyxins in plasma.